Vitamin D3 and K2: Why They Are Paired and How Much You Actually Need

A few years ago vitamin D was sold on its own. Now a large share of the bottles on the shelf say “D3 + K2”, and the price is higher. The combination is sold on a tidy story: D3 pulls calcium in, K2 tells the calcium where to go. The story is broadly correct at the level of biochemistry. Whether it translates into a meaningful benefit at the doses people actually take is a different question, and this article tries to answer it plainly.

What each vitamin does

Vitamin D is a hormone precursor more than a vitamin. Your skin makes it from sunlight, the liver converts it to 25-hydroxyvitamin D (the form measured in blood tests), and the kidneys convert that to the active form. Its best-established job is to increase absorption of calcium and phosphorus from the gut. Without enough vitamin D, calcium absorption falls sharply and bone mineralisation suffers, which in children is rickets and in adults is osteomalacia and, over time, a contribution to osteoporosis.

Vitamin K is needed to activate a family of proteins through a chemical step called carboxylation. The best known are the clotting factors, which is why warfarin, a vitamin K antagonist, thins the blood. Two others matter for the D3 pairing: osteocalcin, which binds calcium into the bone matrix, and matrix Gla protein (MGP), which inhibits calcium deposits in soft tissue, including artery walls. Both proteins are made regardless of vitamin K status, but without enough K they stay in an inactive, uncarboxylated form.

Vitamin K comes in two families. K1 (phylloquinone) is in leafy greens and is mostly used by the liver for clotting. K2 (menaquinones) comes from fermented foods and animal products and is distributed more widely to bone and vessels. K2 itself has subtypes, the two sold as supplements being MK-4 and MK-7.

The logic of pairing them

Put the pieces together and the argument writes itself. Vitamin D increases the amount of calcium entering the body. Vitamin D also increases production of osteocalcin and MGP. Those proteins only work if vitamin K activates them. So, the reasoning goes, taking vitamin D without enough vitamin K raises calcium while leaving the calcium-directing proteins idle, which could in theory favour calcium going to the wrong places.

That is a plausible mechanism, and there is supporting evidence of several kinds:

• Observational data from the Rotterdam Study found that higher dietary menaquinone (K2) intake was associated with lower coronary heart disease mortality and less aortic calcification, while K1 intake was not (Geleijnse et al., 2004).
• A three-year randomised trial in healthy postmenopausal women found 180 mcg of MK-7 daily reduced age-related decline in bone mineral density and bone strength indices compared with placebo (Knapen et al., 2013). A companion trial from the same group reported improved arterial stiffness measures.
• Markers of uncarboxylated osteocalcin and MGP, which indicate functional vitamin K shortage, are common in the general population and fall reliably with K2 supplementation.

What is missing is the direct test: a trial showing that people taking ordinary-dose vitamin D with K2 have better outcomes than people taking vitamin D without it. The hazard the pairing is meant to prevent, vitamin D driving calcium into arteries, has not been demonstrated at normal doses in people with normal kidney function. Large vitamin D trials at 2,000 IU a day have not shown an increase in cardiovascular events.

So the fair summary is this. K2 has evidence of its own for bone and possibly vascular health. Vitamin D has strong evidence for bone health. Taking them together is sensible, especially since most Western diets contain little K2. But the claim that vitamin D is unsafe without K2 is not supported.

How much vitamin D

The Recommended Dietary Allowance set by the National Academies is 600 IU (15 mcg) per day for adults up to age 70 and 800 IU (20 mcg) above 70. The tolerable upper intake level is 4,000 IU (100 mcg) per day (NIH Office of Dietary Supplements).

Those figures assume minimal sun exposure and are aimed at bone health for nearly everyone. In practice:

Situation	Reasonable daily dose	Notes
Healthy adult, some sun, varied diet	600 to 1,000 IU	Covers the RDA; a blood test is not needed
Limited sun, darker skin, northern winter, indoor work	1,000 to 2,000 IU	The most common supplement range; well within the upper limit
Obesity, malabsorption, older adults, documented deficiency	2,000 to 4,000 IU	Stay at or under the upper limit unless a clinician is monitoring
5,000 IU and above	Only with a blood test and a reason	Levels above 100 ng/mL can cause high blood calcium

The 2024 Endocrine Society guideline moved away from recommending routine vitamin D blood testing in healthy adults and away from empiric high doses, suggesting instead that most adults under 75 simply meet the RDA, with higher intakes considered for specific groups such as older adults, pregnant women, people with prediabetes and children (Demay et al., 2024). That is a notable step back from the 2011 guidance that popularised 1,500 to 2,000 IU targets.

If you do get tested, the National Academies regard a 25-hydroxyvitamin D level of 20 ng/mL (50 nmol/L) as sufficient for bone health. Many clinicians prefer 30 ng/mL. There is no established benefit to pushing above 50 ng/mL.

Choose D3 over D2. A meta-analysis of comparison trials found cholecalciferol (D3) raised and sustained 25-hydroxyvitamin D levels more effectively than ergocalciferol (D2) at the same dose (Tripkovic et al., 2012).

How much vitamin K2, and which kind

There is no RDA for vitamin K2 specifically. The Adequate Intake for total vitamin K is 120 mcg per day for men and 90 mcg for women, and no upper limit has been set because no toxicity has been observed from food or supplement forms in people not taking anticoagulants (NIH Office of Dietary Supplements).

Supplement doses of K2 cluster in two ranges:

• MK-7, 90 to 200 mcg per day. This is the range used in the long-term bone trials and is what most D3 + K2 products contain. MK-7 has a half-life measured in days, so one daily dose keeps blood levels steady (Schurgers et al., 2007).
• MK-4, 1,500 mcg to 45 mg per day. MK-4 has a half-life of a few hours and requires large, repeated doses. The 45 mg dose is a prescription osteoporosis treatment in Japan. Low-dose MK-4 in a once-daily combination product is unlikely to maintain blood levels and is mostly label decoration.

For a combination supplement, MK-7 at 90 to 180 mcg is the form and dose with the best match to the evidence. Look for it named explicitly on the panel; “vitamin K2” without a subtype usually means MK-4 at a nominal amount.

Who should be careful

Anyone on warfarin (Coumadin) or similar vitamin K antagonists. Vitamin K2 directly opposes the drug and can push the INR into a range where clots form. This is not a theoretical interaction. Do not start, stop or change a K2 supplement without the prescriber’s agreement. Newer anticoagulants such as apixaban and rivaroxaban do not work through vitamin K and are not affected.

People with high blood calcium or conditions that cause it, including primary hyperparathyroidism, sarcoidosis and some lymphomas. Vitamin D can raise calcium further in these conditions. Supplement only under supervision.

People with chronic kidney disease. Both vitamin D metabolism and calcium handling are altered. Dosing should come from the nephrology team.

Pregnancy. Vitamin D at RDA levels is recommended and is in most prenatal vitamins. K2 supplements have not been studied in pregnancy; dietary vitamin K is fine.

What to look for on the label

1. Vitamin D3 (cholecalciferol), not D2, at 1,000 to 2,000 IU (25 to 50 mcg) per serving for a general-purpose product.
2. Vitamin K2 as MK-7, 90 to 180 mcg per serving. The panel may name it as menaquinone-7. Trademarked forms (MenaQ7, K2VITAL, MK-7 from natto) are fine; the trademark is less important than the dose.
3. A fat-based carrier such as olive, MCT or sunflower oil in a softgel, or a note to take with food.
4. Third-party testing from USP, NSF or an equivalent, because vitamin D potency errors are among the more common failures in independent testing.

Price is mostly driven by MK-7, which is expensive to produce. A product with meaningful MK-7 will rarely be the cheapest option, but it should not need to cost more than a few dollars a month.

Bottom line

Vitamin D3 at 1,000 to 2,000 IU a day is a sound choice for most adults who do not get regular sun, and the 2024 guidance suggests even that is optional for healthy people who eat a reasonable diet. Vitamin K2 as MK-7 at 90 to 180 mcg has its own modest evidence for bone, and possibly for arteries, and is a reasonable thing to pair with it because diets are typically low in K2. What the pairing does not do is make high vitamin D doses safe, and what it must never do is end up in the cabinet of someone taking warfarin.